Arrowstreet Capital’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Arrowstreet Capital’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-205,370	Closed	-$780K	–	2513
2020 Q1	$780K	Buy	+205,370	New	+$885K	﹤0.01%	1394

Other funds holding PGNX

ECM

Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Arrowstreet Capital's PGNX Position: Q2 2020 in Review

Arrowstreet Capital sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 205,370 shares — an estimated $780K sold.

Arrowstreet Capital first reported a position in PGNX in Q1 2020 and held it in 1 quarter. The position peaked at $780K in Q1 2020. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

Arrowstreet Capital reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
Arrowstreet Capital sold 205,370 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $780K.
Arrowstreet Capital first reported a position in Progenics Pharmaceuticals Inc in Q1 2020 and held it in 1 quarter.
Arrowstreet Capital's Progenics Pharmaceuticals Inc position peaked at $780K in Q1 2020.
3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Arrowstreet Capital's 13F filing for Q2 2020, filed 12 Aug 2020.